Celcuity Inc.

NASDAQ:CELC

Biotechnology

Healthcare
$55.60 -4.59%

-$4.04 today

Market cap
$2.72B
Beta
0.12
P/E (TTM)
-23.7
EPS (TTM)
-$3.54
52W Low $11.28High $151.02

Volume 0.98M

Average 1.24M

CELC Debt Repayment

Cash used to repay borrowings during the period.

Celcuity Inc.NASDAQ: CELC

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment outflow grows to $420.4M

Q2 FY2026 debt repayment was $420.4M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $643.15M. Over 3 fiscal years it compounded at +125.2% a year.

Context

  • Debt repayment increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $420.4M or moves back toward the trailing-twelve-month quarterly average of $160.79M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$420.4M— QoQ
Last fiscal yearDec 2025
$222.75M+276.1% YoY
LTMJun 2026
$643.15M+8323485.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+276.1%——
3-year CAGR+125.2%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
222.75M USD
Year-over-year change
+276.1%
4-year CAGR
+98.5%

Debt Repayment vs competitors

How CELC compares with its peers on the latest reported figures

  • CELC's LTM Jun 2026 debt repayment of $643.15M is the largest of the 6 companies compared; the peer median is $16M.
  • Its year-over-year change of +8323485.5% is the highest of 4, against a peer median of +59.8%.
  • Over three fiscal years its annual growth of +125.2% compares with a peer median of +270.4%.
CELC Competitors Peer median
Debt Repayment for CELC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELCCelcuity Inc.LTM Jun 2026$643.15M +8323485.5%+125.2%—
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$160.9M ——52.2%
BLLNBillionToOne, Inc.LTM Jun 2026$28.98M ——7.3%
NEONeoGenomics, Inc.LTM Jun 2026$16M +108.0%+542.7%2.1%
PSNLPersonalis, Inc.LTM Mar 2026$5.1M -449.8%—7.9%
CSTLCastle Biosciences, Inc.LTM Mar 2026$139K +59.8%-2.0%0.0%
Peer median (excluding CELC) $16M+59.8%+270.4%7.3%

Competitors are the stored peer set for CELC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Depreciation & Amortization303.24K210.92K142.77K129.95K167K
Deferred Income Tax00000
Stock-Based Compensation2.61M4.64M4.9M6.99M21.38M
Change in Working Capital819.81K(1.19M)3.86M18.35M(2.65M)
Accounts Receivables(108.76K)95.1K000
Inventory00000
Accounts Payables1.31M1.08M2.43M4.32M(3.04M)
Other Working Capital(377.36K)(2.36M)1.43M14.03M388K
Other Non-Cash Items5.56M704.66K1.06M2.85M4.86M
Operating Cash Flow(20.31M)(36.01M)(53.81M)(83.47M)(153.28M)
Capital Expenditures(81.9K)(158.77K)(97.64K)(249.88K)(249K)
Acquisitions (Net)00000
Purchases of Investments0(143.87M)(314.53M)(705.16M)(396.34M)
Sales of Investments00309.61M642.35M332.51M
Other Investing Activities5000000
Investing Cash Flow(81.4K)(144.03M)(5.01M)(63.07M)(64.08M)
Debt Repayment14.34M19.5M(2.45K)59.23M222.75M
Common Stock Issued78.55M100.5M14.43M63.61M137.85M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities148.02K324.12K50.48M15.55M(46K)
Financing Cash Flow93.04M120.33M64.91M138.39M360.55M
Effect of Forex Changes0000177
Net Change in Cash72.65M(59.71M)6.09M(8.15M)143.19M
Free Cash Flow(20.39M)(36.17M)(53.91M)(83.72M)(153.53M)

Celcuity Inc.

NASDAQ:CELC

Intrinsic Alpha fair value

Locked

Current Price

$55.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.